Pterostilbene vs Resveratrol: Which Is Superior?
Pterostilbene is resveratrol with two methyl groups, and those groups change everything about how it behaves in the body. Including one effect nobody expected.
The Short Answer
Pterostilbene is a dimethylated analogue of resveratrol found in blueberries and heartwood. The two methyl groups make it considerably more lipophilic and shield it from the rapid conjugation that limits resveratrol, giving pterostilbene substantially higher oral bioavailability and a longer half-life. That advantage is real and it does not settle the comparison, because pterostilbene has far less human outcome data and one well-conducted trial found that 250 mg per day raised LDL cholesterol. The honest summary is that pterostilbene delivers more compound to tissue while resveratrol has the larger, if unremarkable, human record.
The Structural Difference and Why It Matters
Resveratrol and pterostilbene are both stilbenes with the same carbon skeleton. Resveratrol carries three hydroxyl groups; pterostilbene has two of them replaced by methoxy groups.
Hydroxyl groups are the handles that phase II metabolism grabs. Sulfotransferases and UDP-glucuronosyltransferases attach sulfate and glucuronide to them within minutes of absorption, which is why the great majority of an oral resveratrol dose is inactivated before it reaches circulation. Replacing two of the three with methoxy groups removes two of those handles.
The result is a compound that is more lipophilic, crosses membranes more readily including the blood-brain barrier, resists first-pass conjugation better, and persists longer in plasma. Comparative pharmacokinetic work in animals reports oral bioavailability for pterostilbene several times that of resveratrol, with a half-life measured in hours rather than minutes.
Mechanistically, Are They the Same?
Broadly yes, with differences of emphasis.
Both activate AMPK, which is the best-supported route by which either affects metabolism, and both increase NAD+ availability downstream of that. Both modulate NF-kB inflammatory signalling and both behave as hormetic stressors at moderate concentrations. Neither directly activates SIRT1 in the way the early resveratrol literature claimed, since that finding depended on a modified assay substrate.
Pterostilbene shows stronger activity in some neurological models, consistent with better central nervous system penetration, and it has been studied more for cognitive endpoints. Resveratrol has the larger literature on vascular endothelial function.
The important point for anyone choosing between them: the mechanistic difference is smaller than the pharmacokinetic difference. This is a delivery comparison more than a biology comparison.
The Human Evidence, Side by Side
| Resveratrol | Pterostilbene | |
|---|---|---|
| Oral bioavailability | Very low; extensive first-pass conjugation | Several times higher in comparative animal work |
| Half-life | Minutes for the free compound | Hours |
| Blood-brain barrier | Limited | Better, being more lipophilic |
| Human trial volume | Large; dozens of randomised trials | Small; a handful of trials |
| Metabolic outcomes | Small improvements in impaired glucose handling | Limited data; some blood pressure signal |
| Lipids | Neutral to mildly favourable | LDL cholesterol increased at 250 mg/day in one trial |
| Cognitive outcomes | Mixed to null | Early and limited |
| Typical dose | 150 to 500 mg/day | 50 to 250 mg/day |
The LDL Finding
This deserves its own section because it is the single most decision-relevant human result for pterostilbene and it is rarely mentioned in product marketing.
A randomised placebo-controlled trial in adults with elevated cholesterol tested pterostilbene at 125 mg twice daily, at 50 mg twice daily, and at 125 mg twice daily combined with a grape extract. The higher pterostilbene dose taken alone was associated with an increase in LDL cholesterol and total cholesterol relative to placebo. The combination arm did not show the same increase. Blood pressure fell modestly in the pterostilbene arms.
One trial is one trial, and the mechanism is not established. But it is a properly randomised human result in the direction nobody wanted, in a compound taken largely for cardiometabolic reasons, and it means anyone using pterostilbene at the higher end of the dose range has a specific reason to check a lipid panel rather than assume neutrality.
Safety and Practical Considerations
Pterostilbene is well tolerated in the trials conducted, with no characteristic adverse profile at 50 to 250 mg per day over weeks to months. Long-term human safety is unestablished, as the trials are short and few.
Two considerations carry over from resveratrol. Both compounds have mild antiplatelet activity, which matters alongside anticoagulant therapy and before procedures. And both interact with cytochrome P450 enzymes, so a medication check is appropriate.
The exercise interference finding reported for resveratrol in older men, where it blunted several training adaptations, has not been tested for pterostilbene. Given the shared hormetic and antioxidant character, applying the same caution to pterostilbene around the training window is the conservative reading.
Product-wise, pterostilbene is frequently sold combined with nicotinamide riboside. The pairing has a mechanistic rationale through NAD+ and sirtuin signalling and no controlled human trial showing the combination outperforms the precursor alone.
Choosing Between Them
A structured answer, given what the evidence supports rather than what the marketing claims:
- If the objective is metabolic support with the largest human record: resveratrol at 150 to 250 mg with a fat-containing meal, accepting that the effects are small and concentrated in people with impaired glucose handling.
- If the objective is tissue exposure and a cognitive or central nervous system rationale: pterostilbene at 50 to 100 mg per day, staying below the dose associated with the LDL finding, with a lipid panel before and after.
- If either is being taken alongside serious training: separate it from the training window.
- If neither has a defined objective and observation window: the honest answer is that this compound class is second-order, and the money is better spent elsewhere in the stack.
The broader lesson from this pairing is worth more than either compound. Improving the pharmacokinetics of a molecule with modest demonstrated benefit does not automatically improve the benefit, and it can surface effects the poorly absorbed parent never showed.
The AEONNN Perspective
This comparison is where the Pharmacokinetics and Evidence layers pull in opposite directions, which is exactly the situation a single blended score would misrepresent. Pterostilbene wins on delivery. Resveratrol wins on human record. AEONNN presents that tension rather than resolving it artificially, because the right answer depends on what a member is trying to achieve and what they are willing to be uncertain about.
The LDL finding is also a case study in why the Evidence layer has to include inconvenient results. A system that indexed only favourable trials would rank pterostilbene above resveratrol without qualification. The Safety layer then adds a concrete action: for a member using the higher dose, a lipid panel is part of the protocol rather than an afterthought.
Both compounds map to Cellular Energy and Repair and Metabolic and Cardiovascular Health, and both sit at Evidence Level B or C depending on the outcome in question. Neither belongs in a foundational stack, which is what Stack Builder reflects when a member has not yet addressed training, sleep and body composition.
Pillar Matrix mapping
Cellular Energy and Repair, Metabolic and Cardiovascular Health, Longevity and Biological Age
Database Matrix layers
- Pharmacokinetics Layer (HMDB, PubChem)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Safety Layer (DrugBank, FAERS)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
Is pterostilbene better than resveratrol?
It is better absorbed, more lipophilic and longer lasting, with several times the oral bioavailability in comparative animal work. It has far less human outcome data, and one randomised trial found 250 mg per day raised LDL cholesterol. Better delivery is not the same as better evidence.
How much pterostilbene should be taken?
Trials have used 50 to 250 mg per day. The lipid finding appeared at 125 mg twice daily, so staying at the lower end and checking a lipid panel is the conservative approach.
Does pterostilbene raise cholesterol?
One randomised placebo-controlled trial found an increase in LDL and total cholesterol at 125 mg twice daily taken alone, but not when combined with grape extract. It is a single trial, unexplained mechanistically, and specific enough to warrant checking your own lipids.
Why is pterostilbene absorbed so much better?
Two of resveratrol three hydroxyl groups are replaced by methoxy groups. Hydroxyl groups are the sites where sulfation and glucuronidation inactivate the compound on first pass, so removing two of them substantially reduces that clearance.
Do they work through sirtuins?
Not directly. The original claim that resveratrol activates SIRT1 depended on a modified assay substrate. Both compounds appear to act mainly through AMPK activation, which raises NAD+ availability and increases sirtuin activity indirectly.
Is the pterostilbene plus nicotinamide riboside combination better?
The rationale is coherent through NAD+ and sirtuin signalling, and no controlled human trial has shown the combination outperforming the precursor alone.
Should pterostilbene be avoided around exercise?
It has not been tested, but resveratrol blunted several training adaptations in a trial in older men, and the two share hormetic and antioxidant character. Separating a dose from the training window is the conservative reading.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.